Literature DB >> 10676444

Pain inhibition by endomorphins.

R Przewłocki1, D Labuz, J Mika, B Przewłocka, C Tomboly, G Toth.   

Abstract

Spinal analgesic effects of endomorphin-1 and endomorphin-2 were studied during acute, inflammatory, and neuropathic pain in rats chronically implanted with intrathecal cannulas. Endomorphin-1 and endomorphin-2 (2.5-10 micrograms i.t.), as well as their analogues, increased the tail-flick and the paw pressure latencies. In a model of inflammatory pain, the formalin-induced behavior was attenuated by endomorphins; however, the effect studied was not dose-dependent and was less pronounced in comparison with that evoked by morphine. On the other hand, in rats with a sciatic nerve injury (crush), endomorphins antagonized allodynia in a dose-dependent manner, whereas morphine was found to be ineffective in a similar dose range. Endomorphins also exhibited an antinociceptive potency in rats tolerant to morphine. In conclusion, our results show a powerful analgesic action of endomorphins at the spinal level. The most interesting finding is a strong effect of endomorphins in neuropathic pain, which opens up a possibility of using these compounds in pain therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10676444     DOI: 10.1111/j.1749-6632.1999.tb07887.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Agonist-dependent attenuation of mu-opioid receptor-mediated G-protein activation in the dorsal root ganglia of neuropathic rats.

Authors:  Ilona Obara; Ozge Gunduz Cinar; Katarzyna Starowicz; Sandor Benyhe; Anna Borsodi; Barbara Przewlocka
Journal:  J Neural Transm (Vienna)       Date:  2010-03-06       Impact factor: 3.575

2.  Endomorphin 1 and endomorphin 2 suppress in vitro antibody formation at ultra-low concentrations: anti-peptide antibodies but not opioid antagonists block the activity.

Authors:  Benito Anton; Phillipe Leff; Juan C Calva; Rodolfo Acevedo; Alberto Salazar; Maura Matus; Lenin Pavón; Martin Martinez; Joseph J Meissler; Martin W Adler; John P Gaughan; Toby K Eisenstein
Journal:  Brain Behav Immun       Date:  2008-04-18       Impact factor: 7.217

3.  Spinal endomorphin 2 antinociception and the mechanisms that produce it are both sex- and stage of estrus cycle-dependent in rats.

Authors:  Nai-Jiang Liu; Alan R Gintzler
Journal:  J Pain       Date:  2013-09-29       Impact factor: 5.820

4.  Experimental Gene Therapy with Serine-Histogranin and Endomorphin 1 for the Treatment of Chronic Neuropathic Pain.

Authors:  Stanislava Jergova; Catherine E Gordon; Shyam Gajavelli; Jacqueline Sagen
Journal:  Front Mol Neurosci       Date:  2017-12-08       Impact factor: 5.639

5.  Endomorphin-2 Inhibition of Substance P Signaling within Lamina I of the Spinal Cord Is Impaired in Diabetic Neuropathic Pain Rats.

Authors:  Fa-Ping Wan; Yang Bai; Zhen-Zhen Kou; Ting Zhang; Hui Li; Ya-Yun Wang; Yun-Qing Li
Journal:  Front Mol Neurosci       Date:  2017-01-10       Impact factor: 5.639

6.  Preemptive intrathecal administration of endomorphins relieves inflammatory pain in male mice via inhibition of p38 MAPK signaling and regulation of inflammatory cytokines.

Authors:  Ting Zhang; Nan Zhang; Run Zhang; Weidong Zhao; Yong Chen; Zilong Wang; Biao Xu; Mengna Zhang; Xuerui Shi; Qinqin Zhang; Yuanyuan Guo; Jian Xiao; Dan Chen; Quan Fang
Journal:  J Neuroinflammation       Date:  2018-11-15       Impact factor: 8.322

7.  Spinal changes of a newly isolated neuropeptide endomorphin-2 concomitant with vincristine-induced allodynia.

Authors:  Yang Yang; Yong-Gang Zhang; Guo-An Lin; He-Qiu Xie; Hai-Tao Pan; Ben-Qing Huang; Ji-Dong Liu; Hui Liu; Nan Zhang; Li Li; Jian-Hua Chen
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

8.  Simultaneous intrathecal injection of muscimol and endomorphin-1 alleviates neuropathic pain in rat model of spinal cord injury.

Authors:  Marjan Hosseini; Zohreh Karami; Mahmood Yousefifard; Atousa Janzadeh; Elham Zamani; Farinaz Nasirinezhad
Journal:  Brain Behav       Date:  2020-03-18       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.